相关临床试验
4
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2020
进行中（未招募）
3
75.0%
撤回
1
25.0%
暂无批准数据
- Mana.bio has appointed Dr. Laura Sepp-Lorenzino, former CSO of Intellia Therapeutics, to its Scientific Advisory Board to guide the company's AI-driven LNP discovery platform. - Dr. Sepp-Lorenzino brings decades of leadership experience from Intellia, Vertex Pharmaceuticals, Alnylam, and Merck, spanning CRISPR, RNAi, and nucleic acid therapies. - Mana.bio's proprietary AI/ML platform leverages the world's largest curated LNP dataset to predict safety, tropism, and stability, with NHP-validated delivery solutions for extrahepatic targets. - The appointment comes at what CEO Yogev Debbi describes as a pivotal stage of growth as the company scales its discovery engine and expands its therapeutic pipeline.
- Over 180 companies are advancing 250+ AAV-based gene therapy candidates globally, spanning preclinical through marketed stages, according to DelveInsight's 2026 pipeline assessment. - The FDA granted approval to Otarmeni, the first dual-AAV gene therapy for OTOF-related genetic hearing loss, and accepted Ultragenyx's BLA for UX111 in Sanfilippo syndrome Type A with a September 2026 PDUFA date. - Taysha Gene Therapies reported FDA alignment on a BLA pathway for TSHA-102 in Rett syndrome, with pivotal REVEAL trial enrollment progressing and manufacturing validation underway. - Sensorion's SENS-501 demonstrated durable efficacy and favorable safety at six months in a Phase I/II trial for otoferlin-related congenital hearing loss, while GJB2-GT advances toward regulatory filing.
- Taysha Gene Therapies received FDA Breakthrough Therapy designation for TSHA-102 and secured regulatory alignment on the pivotal Part B REVEAL trial design for Rett syndrome treatment. - Goldman Sachs upgraded its rating on the company following TSHA-102's progression into Phase 3 development, highlighting the regulatory clarity and clinical momentum. - The company has dosed the first patient in its REVEAL pivotal trial and obtained FDA alignment on safety data for its planned BLA submission. - Analyst consensus projects revenue of $88.9 million and earnings of $14.1 million by 2028, with fair value estimates ranging from $10.54 to $19.11 per share.
- Taysha Gene Therapies stock declined 11.22% following recent CEO departure news, highlighting ongoing leadership instability at the gene therapy company. - The company reported severe financial distress with negative profit margins of -1144% EBIT and -1121.7% EBITDA, despite maintaining a substantial cash reserve of $312 million. - Despite a 100% gross margin, operational inefficiencies and a high price-to-sales ratio of 171.13 suggest potential overvaluation relative to current revenue generation of $8.3 million. - Technical analysis shows bearish sentiment with stock trading between resistance at $5.17 and support around $4.50, with declining volume indicating waning investor interest.
- Signify Bio secured an oversubscribed $15 million initial financing round led by Actium Group with participation from Gates Foundation Strategic Investment Fund, Danaher Ventures, Eli Lilly, and American Cancer Society's BrightEdge. - The Dallas-based biotech company has developed three proprietary platforms including the SEND system for controlling protein secretion and localization, and iPhos lipid nanoparticles for targeted delivery. - The company aims to transform the human body into a biofactory for personalized protein therapeutics by combining signal peptide engineering with mRNA-encoded design capabilities. - Signify Bio maintains a strategic partnership with UT Southwestern Medical Center, providing access to scalable manufacturing and broad scientific expertise for advancing nucleic acid therapeutics.
- Taysha Gene Therapies has received FDA alignment on key elements of the TSHA-102 pivotal trial design for Rett syndrome, with the agency advising direct submission of trial protocol as an IND amendment, potentially expediting study initiation. - Both high and low doses of TSHA-102 continue to demonstrate favorable safety profiles with no treatment-related serious adverse events or dose-limiting toxicities across 10 patients in the REVEAL trials as of April 2025. - The company plans to provide comprehensive updates on pivotal trial design, natural history data analysis, and clinical data from both REVEAL trials during the International Rett Syndrome Foundation Scientific Meeting in Q2 2025.
- A comprehensive 2025 pipeline analysis identifies over 20 companies developing more than 20 therapeutic candidates for Rett syndrome, highlighting significant industry investment in this rare neurological disorder. - Anavex Life Sciences leads with blarcamesine in Phase III trials, representing the most advanced treatment targeting SIGMA1 and muscarinic receptors to restore cellular homeostasis. - Gene therapy approaches dominate the pipeline with TSHA-102 and NGN-401 delivering MECP2 gene replacement using AAV9 vectors in Phase I/II trials. - The therapeutic landscape spans multiple modalities including small molecules, gene therapies, and biologics, addressing the critical unmet medical need in Rett syndrome treatment.
- Peter Marks, head of FDA's Center for Biologics Evaluation and Research since 2016, was forced to resign after refusing to support HHS Secretary Robert F. Kennedy Jr.'s vaccine safety claims. - The departure triggered significant stock declines for gene therapy and vaccine-focused companies including Taysha, Solid Biosciences, Sarepta and Novavax, with shares falling 5-10%. - Industry leaders express concern that FDA's scientific independence is under threat, with BMO Capital Markets analysts calling the resignation "a significant negative for the biopharma and biotech sectors." - Marks' exit follows other key FDA departures, including CDER head Patrizia Cavazzoni, raising questions about regulatory stability and the future of accelerated approvals for innovative therapies.
• Neurogene has suspended enrollment in the high-dose arm of its NGN-401 gene therapy trial for Rett syndrome after a patient developed life-threatening systemic hyperinflammatory syndrome, a known risk with AAV vector therapies. • Despite early efficacy signals showing "meaningful gains of skills and developmental milestones" in low-dose patients, the company's shares plummeted nearly 44% following the safety concerns announcement. • The trial will continue with the low-dose cohort, though with delayed enrollment timeline, as the company works to balance promising efficacy data against serious safety considerations for this devastating neurological disorder.
• Two companies, Neurogene and Taysha Gene Therapies, are in Phase 1/2 clinical trials with gene therapies targeting the MECP2 gene for Rett syndrome. • These therapies aim to address the underlying genetic cause of Rett syndrome, unlike existing treatments that only manage symptoms. • Both companies have incorporated regulatory mechanisms to ensure precise MECP2 expression, avoiding complications from overexpression. • Preliminary data from ongoing trials are expected in late 2024 and early 2025, offering hope for a potential disease-modifying treatment.
